Literature DB >> 1663598

Mu and delta opiate receptors in neuronal and astroglial primary cultures from various regions of the brain--coupling with adenylate cyclase, localisation on the same neurones and association with dopamine (D1) receptor adenylate cyclase.

P S Eriksson1, E Hansson, L Rönnbäck.   

Abstract

Primary cultures, enriched in neurones or astroglial cells, from three phylogenetically different regions of the brain of the rat, the cerebral cortex, the striatum and the brain stem, were used to investigate the presence of opiate receptors, coupled to adenylate cyclase. Morphine was used as a mu-receptor agonist and [D-Ala2, D-Leu5]-enkephalin (DADLE) was used as a delta-receptor agonist. In the neuronal cultures, both ligands inhibited the prostaglandin (PG)E1-stimulated intracellular accumulation of cyclic AMP dose-dependently, with the most prominent effects seen in the cultures of striatum and with DADLE being more potent than morphine. The opiate receptor antagonist, naloxone reversed the effects. Morphine and DADLE, added together, inhibited the PGE1-stimulated accumulation of cyclic AMP, less than the sum of the effects of each drug. Therefore, it might be that these opioid receptors are localized together on the same neurone. Striatal neurones contained dopamine receptors coupled to cyclic AMP, as second messenger. It was shown that the D1 (dopamine) receptor-stimulated activity of adenylate cyclase was inhibited by the mu and delta opioid receptor ligands. Thus, interactions at the level of adenylate cyclase seem to exist between D1, mu and delta opiate receptors. In the astroglial enriched cultures, DADLE inhibited the PGE1-induced accumulation of cyclic AMP, however, with a less prominent effect in the brain stem cultures.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663598     DOI: 10.1016/0028-3908(91)90170-g

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  19 in total

1.  CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates.

Authors:  Nazira El-Hage; Guanghan Wu; Jayakrishna Ambati; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmunol       Date:  2006-07-10       Impact factor: 3.478

Review 2.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

3.  Ultrastructural immunocytochemical localization of mu-opioid receptors in rat nucleus accumbens: extrasynaptic plasmalemmal distribution and association with Leu5-enkephalin.

Authors:  A L Svingos; A Moriwaki; J B Wang; G R Uhl; V M Pickel
Journal:  J Neurosci       Date:  1996-07-01       Impact factor: 6.167

4.  Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade.

Authors:  L M Bohn; M M Belcheva; C J Coscia
Journal:  J Neurochem       Date:  2000-02       Impact factor: 5.372

5.  Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappa-opioid receptor expression among cultured mouse astrocytes.

Authors:  A Stiene-Martin; R Zhou; K F Hauser
Journal:  Glia       Date:  1998-03       Impact factor: 7.452

Review 6.  Self-injurious behaviour in autistic children: a neuro-developmental theory of social and environmental isolation.

Authors:  Darragh P Devine
Journal:  Psychopharmacology (Berl)       Date:  2013-09-21       Impact factor: 4.530

7.  Morphine and gp120 toxic interactions in striatal neurons are dependent on HIV-1 strain.

Authors:  Elizabeth M Podhaizer; Shiping Zou; Sylvia Fitting; Kimberly L Samano; Nazira El-Hage; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-19       Impact factor: 4.147

8.  Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro.

Authors:  S K Buch; V K Khurdayan; S E Lutz; P E Knapp; N El-Hage; K F Hauser
Journal:  Neuroscience       Date:  2007-05-02       Impact factor: 3.590

9.  CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice.

Authors:  Nazira El-Hage; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2008-09-25       Impact factor: 4.147

10.  Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.

Authors:  Theresa-Alexandra M Mattioli; Brian Milne; Catherine M Cahill
Journal:  Mol Pain       Date:  2010-04-16       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.